Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19266 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Yotaro Motomura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. Hauptthemen laut MEDLINE: Retinal Neoplasms, Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Primary vitreoretinal lymphoma (PVRL) is a rare subtype of malignant lymphoma with a poor prognosis because of high frequency of central nervous system (CNS) progression. Identification of factors associated with CNS progression is essential to improve the prognosis of patients with PVRL. We conducted a retrospective study of 54 patients diagnosed with PVRL and treated at our hospital to identify factors associated with CNS progression and prognosis. All patients were treated with intravitreal methotrexate (MTX) injections in the affected eyes until lesion resolution. Twenty‐four patients were treated with systemic administration of high‐dose MTX (systemic HD‐MTX) every other week for a total of five cycles following intravitreal MTX injection. Of 24 patients, 20 completed five cycles of systemic HD‐MTX. The 5‐year cumulative incidence of CNS progression and overall survival (OS) rate were 78.0% and 69.0% respectively. By univariate and multivariate analyses, bilateral disease and the detection of B‐cell clonality confirmed by flow cytometric analysis were risk factors associated with CNS progression. Moreover, systemic HD‐MTX completion reduced the risk of CNS progression and was identified as a factor affecting OS. In this study, factors for CNS progression identified may potentially contribute to the optimized therapeutic stratification to improve the survival of patients with PVRL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
- Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
- Department of Hematology and Biophysical Systems Analysis, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
- Department of Laboratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
ORCID-Profile: Kota Yoshifuji, Ayako Arai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Motomura, Y., Yoshifuji, K., Tachibana, T., Takase, H., Arai, A., Tanaka, K., Okada, K., Nogami, A., Umezawa, Y., Sakashita, C., Yamamoto, M., Mori, T., & Nagao, T. (2024). Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.19266
Vancouver
Motomura Y, Yoshifuji K, Tachibana T, Takase H, Arai A, Tanaka K, et al. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma. British Journal of Haematology. 2024. doi:10.1111/bjh.19266
BibTeX
@article{Motomura2024,
author = {Motomura, Yotaro and Yoshifuji, Kota and Tachibana, Takayoshi and Takase, Hiroshi and Arai, Ayako and Tanaka, Keisuke and Okada, Keigo and Nogami, Ayako and Umezawa, Yoshihiro and Sakashita, Chizuko and Yamamoto, Masahide and Mori, Takehiko and Nagao, Toshikage},
title = {Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19266}
}
EUVIMED